新入荷 再入荷

Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial - The Journal of Thoracic and Cardiovascular Surgery

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 10800円 (税込)
数量

Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial - The Journal of Thoracic and Cardiovascular Surgery

Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage  II-IIIA non–small cell lung cancer in the randomized phase III IMpower010  trial - The Journal of Thoracic and Cardiovascular SurgerySafety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial - The Journal of Thoracic and Cardiovascular Surgery,肝臓の問題 | オステオパシー 東京渋谷  OMT-LAB Osteopathy Shibuya Tokyo肝臓の問題 | オステオパシー 東京渋谷  OMT-LAB Osteopathy Shibuya Tokyo,Clinical and molecular characterization of long-term survivors with  extensive-stage small cell lung cancer treated with first-line atezolizumab  plus carboplatin and etoposide - Lung CancerClinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide - Lung Cancer,Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy  contributes to the antitumor effect of mitochondrial complex I inhibition:  Cell ReportsEndogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition: Cell Reports,ASCO GU 2020: New Standards in First-Line Therapy for Advanced DiseaseASCO GU 2020: New Standards in First-Line Therapy for Advanced Disease

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です